| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $2.7M | — | +34.8% |
| SG&A Expense | $5.9M | — | +88.9% |
| Operating Income | -$8.6M | — | -67.7% |
| Interest Expense | $375K | — | — |
| Net Income | -$9.0M | — | -77.2% |
| EPS (Basic) | -$0.31 | — | +26.2% |
| EPS (Diluted) | -$0.31 | — | +26.2% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $6.4M | -26.9% | +59.8% |
| Current Assets | $7.3M | -26.4% | +43.1% |
| Total Assets | $7.4M | -26.2% | +31.3% |
| Current Liabilities | $6.0M | -40.1% | +78.5% |
| Total Liabilities | $6.0M | -40.2% | +70.9% |
| Stockholders' Equity | $1.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$9.0M | — | -127.6% |
| Financing Cash Flow | $6.8M | — | +81.6% |
| -38.3% |